The Pharmacy Industry in Øvre Eiker: Companies, Statistics, and Outlooks

Pharmacies in Øvre Eiker form a stable, but dynamic sector with three registered companies in the municipality. The three pharmacies are located in Hokksund, where most of the local employees and economic activities are concentrated. Øvre Eiker has shown a mix of growth and challenges over the past few years, with a significant sales decline in 2017 followed by a gradual increase since. This shows that the sector has both security and potential for further development.

Economic data shows that sales for the pharmacy industry in Øvre Eiker have varied significantly over time. After a sharp decline of -52.3% from 2016 to 2017, sales increased by 93.6% from 2017 to 2018 and continued to grow gradually until 2024, reaching NOK 106.4 million. In 2025, a decline of -8.8% was recorded, but there is still a positive trend over the past few years. The number of employees has been more stable, with an increase from 26 to 35 employees from 2021 to 2023, followed by a decline in 2025. This shows that the sector has both security and potential for further development.

Annual sales and employees for the pharmacy industry in Øvre Eiker

In Øvre Eiker, there are three registered pharmacy companies in the industry, all with AS as the organizational form. These companies are:

1. Apotek 1 Eiker Senter – Eiker shopping centre, Prestebråtan, Hokksund. 25 employees, established 2006. Operating income: NOK 39.3M, sales: NOK 38.7M, EBITDA: NOK 2.8M.
2. Hokksund Farmasi As – Stasjonsgata 27, Hokksund. 7 employees, established 2002. Operating income: NOK 32.0M, sales: NOK 32.0M, EBITDA: NOK 762K.
3. Boots Apotek Hokksund – Stasjonsgata 71, Hokksund. 4 employees, established 1965. Operating income: NOK 15.0M, sales: NOK 15.0M, EBITDA: NOK 270.9K.

All companies are still in operation, and there are no registered bankruptcies in the industry in the municipality.

Pharmacy activity in Øvre Eiker is concentrated in Hokksund, where three companies are registered with a total of 36 employees. Economic data for Hokksund shows an operating income of NOK 86.3M, sales of NOK 85.7M, and EBITDA of NOK 3.9M. This shows that Hokksund is an important economic hub for the pharmacy industry in the municipality.

The industry has proven to be stable over time, with no registered bankruptcies for pharmacy companies in Øvre Eiker. This indicates that the sector has a good level of security, even though there have been variations in sales and number of employees. The three companies have shown different economic performance, with Apotek 1 Eiker Senter having the highest EBITDA margin (7%) compared to the others. This may indicate that the company has an efficient operational model, while the other companies have lower margins and fewer employees.

For entrepreneurs considering establishing themselves in the pharmacy industry in Øvre Eiker, the data shows a sector with both growth potential and stability. Sales have grown strongly from 2018 to 2024, with an increase of over 40%, and the number of employees has also increased over time. This suggests that there is a need for pharmacy services in the municipality, especially in Hokksund. At the same time, it is important to be aware of the periodic declines in sales, which were recorded in 2025. Entrepreneurs should also consider analyzing competitors' economic data and find ways to differentiate themselves, for example through customer adaptation or digital solutions. SmartGrunder can help find suitable addresses and develop strategies to ensure competitiveness in this market segment.

The pharmacy industry in Øvre Eiker proves to be a stable, but dynamic sector with growth potential. With three companies and a concentration of activity in Hokksund, it is clear that the municipality plays an important role in pharmacy services in the region. The economic trends show that the sector has both security and opportunities for further development, especially with the positive trend in sales and number of employees over the past few years. Entrepreneurs should consider capitalizing on this growth, while also taking into account the periodic challenges in market data.